

## Special Issue

# New Advance in Immuno-Oncology

### Message from the Guest Editor

Immune system plays an important role in tumor development, acting by means of both innate and adaptive immunity. The immune surveillance mechanism is a dynamic process characterized by three phases: Elimination, Equilibrium and Escape. Thus, the immune system not only protects against cancer development but also shapes emerging tumors.

Moreover, the cancer cells could express molecules inhibiting the immune response, such as PD-L1. Recent studies demonstrated the association between immune cells infiltration of tumor tissue or circulating immune cells and prognosis or response to anticancer treatment in various cancer types. Moreover, different anticancer treatment, including target therapy, chemotherapy and radiotherapy, are able to modify patients' immune-fitness. This Special Issue "New Advance in Immuno-Oncology" will include reviews and original research focusing on the role of the immune system in tumour development, on predictive or prognostic immune biomarkers identification, and on new treatments in immuno-oncology field in all types of solid tumor.

### Guest Editor

Dr. Concetta Elisa Onesti

National Cancer Institute, "Regina Elena", Rome, Italy

### Deadline for manuscript submissions

closed (31 October 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/78537](https://mdpi.com/si/78537)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).